RxDoctor Payments Data

Robert Bass, MD

Gastroenterology · Jacksonville Beach, FLNPI 1457328726

Payments from drug & device makers

$12,609in general payments, 2019–2025

Across 267 payments — averaging $47.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Research Incorporated$7K
  • Merit Medical Systems Inc$2K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$532
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$440
  • plus $930 from 15 others

What the payments were for

  • Royalty or licence$1,80831%
  • Consulting fees$120%
  • Food & beverage$3,98868%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,609 in reported general payments places this provider in the 75th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$164,259
Medicare patients
529
Services billed
1,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab21$550,438
RinvoqUpadacitinib16$101,069
Esomeprazole Magnesium159$7,778
Budesonide DrBudesonide36$5,377
Dexlansoprazole DrDexlansoprazole13$4,597
Budesonide EcBudesonide11$4,315
Mesalamine12$4,185
Famotidine150$3,478
Mesalamine ErMesalamine16$3,121
Omeprazole142$3,044
Ursodiol17$1,461
Dicyclomine Hcl77$1,457
CholestyramineCholestyramine (With Sugar)17$1,019
Pantoprazole Sodium41$484
Sucralfate17$386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,010$550,43821 claims
AbbVieRinvoq$1,187$101,06916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Jacksonville Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →